Compare BARK & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BARK | ADCT |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.2M | 483.1M |
| IPO Year | N/A | 2020 |
| Metric | BARK | ADCT |
|---|---|---|
| Price | $0.54 | $3.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $2.50 | ★ $7.60 |
| AVG Volume (30 Days) | 921.1K | ★ 1.2M |
| Earning Date | 02-04-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $451,690,000.00 | $75,209,000.00 |
| Revenue This Year | N/A | $10.36 |
| Revenue Next Year | $5.02 | $3.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.35 |
| 52 Week Low | $0.53 | $1.05 |
| 52 Week High | $2.32 | $4.80 |
| Indicator | BARK | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 30.69 | 47.55 |
| Support Level | $0.55 | $3.38 |
| Resistance Level | $0.62 | $3.66 |
| Average True Range (ATR) | 0.04 | 0.20 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 5.18 | 45.39 |
BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).